Human Kidney 2 cell showing actin assemblies around endosomes in OCRL1 deficient cells (actin white, endosomes in yellow and pink and nuclei in blue). **Joint Press release from Bambino Gesù ...
Can-Fite Signed agreement with Fondazione Telethon for co-development of Piclidenoson for the treatment of Lowe syndrome an estimated $100 M market in the U.S. only with no drug available FDA & EMA ...
Can-Fite BioPharma Initiates Phase II Clinical Study for Piclidenoson in Patients with Lowe Syndrome
Can-Fite BioPharma Ltd. has announced the completion of a Phase II study design and is preparing to initiate a clinical study for Piclidenoson, a novel treatment for Lowe Syndrome, a rare genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results